Adjuvants for peptide-based cancer vaccines
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possi...
Saved in:
Main Authors: | Willem W Overwijk, Hiep Khong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2016-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/4/1/56.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines
by: Sanchari Paul, et al.
Published: (2025-12-01) -
Lipoprotein Signal Peptide as Adjuvants: Leveraging Lipobox-Driven TLR2 Activation in Modern Vaccine Design
by: Muhammad Umar, et al.
Published: (2025-01-01) -
Vaccine oil adjuvants for the development of aquaculture
by: J. B. Arous, et al.
Published: (2018-04-01) -
Peptide-Based Vaccination Therapy for Rheumatic Diseases
by: Bin Wang, et al.
Published: (2020-01-01) -
WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
by: Yoshihiro Oka, et al.
Published: (2007-01-01)